# Correction: CBL0137 and NKG2A blockade: a novel immuno-oncology combination therapy for Myc-overexpressing triple-negative breast cancers

**Authors:** Prahlad V. Raninga, Bijun Zeng, Davide Moi, Ethan Trethowan, Federica Saletta, Pooja Venkat, Chelsea Mayoh, Rochelle C. J. D’Souza, Bryan W. Day, Tyler Shai-Hee, Orazio Vittorio, Roberta Mazzieri, Riccardo Dolcetti, Kum Kum Khanna

PMC · DOI: 10.1038/s41388-025-03319-x · Oncogene · 2025-03-03

## Full-text entities

- **Genes:** MYC (MYC proto-oncogene, bHLH transcription factor) [NCBI Gene 4609] {aka MRTL, MYCC, bHLHe39, c-Myc}, KLRC1 (killer cell lectin like receptor C1) [NCBI Gene 3821] {aka CD159A, NKG2, NKG2A}
- **Diseases:** triple-negative breast cancers (MESH:D064726)
- **Chemicals:** CBL0137 (MESH:C000600493)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC11932919/full.md

---
Source: https://tomesphere.com/paper/PMC11932919